MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors
| Autor: | Atallah, EL, Maheshwari, V, Mauro, MJ, Boquimpani, C, Réa, D, Hochhaus, A, Minami, Y, Saini, L, Corbin, R |
|---|---|
| Zdroj: | In Value in Health July 2022 25(7) Supplement:S521-S521 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect